- Home
- SDRL vs SUPN Comparison
SDRL vs SUPN Comparison
Compare SDRL & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDRL
- SUPN
- Stock Information
- Founded
- SDRL 2005
- SUPN 2005
- Country
- SDRL Bermuda
- SUPN United States
- Employees
- SDRL N/A
- SUPN 674
- Industry
- SDRL Oil & Gas Production
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- SDRL Energy
- SUPN Health Care
- Exchange
- SDRL Nasdaq
- SUPN Nasdaq
- Market Cap
- SDRL 2.0B
- SUPN 2.5B
- IPO Year
- SDRL N/A
- SUPN 2012
- Fundamental
- Price
- SDRL $32.78
- SUPN $46.00
- Analyst Decision
- SDRL Strong Buy
- SUPN Buy
- Analyst Count
- SDRL 4
- SUPN 2
- Target Price
- SDRL $56.67
- SUPN $43.00
- AVG Volume (30 Days)
- SDRL 808.3K
- SUPN 809.3K
- Earning Date
- SDRL 08-06-2025
- SUPN 11-03-2025
- Dividend Yield
- SDRL N/A
- SUPN N/A
- EPS Growth
- SDRL N/A
- SUPN 1411.53
- EPS
- SDRL 1.21
- SUPN 1.14
- Revenue
- SDRL $1,289,000,000.00
- SUPN $665,125,000.00
- Revenue This Year
- SDRL $4.64
- SUPN $4.84
- Revenue Next Year
- SDRL $1.16
- SUPN $17.69
- P/E Ratio
- SDRL $27.00
- SUPN $40.09
- Revenue Growth
- SDRL N/A
- SUPN 5.55
- 52 Week Low
- SDRL $17.74
- SUPN $29.16
- 52 Week High
- SDRL $42.41
- SUPN $46.08
- Technical
- Relative Strength Index (RSI)
- SDRL 67.08
- SUPN 73.94
- Support Level
- SDRL $30.56
- SUPN $44.10
- Resistance Level
- SDRL $33.38
- SUPN $45.94
- Average True Range (ATR)
- SDRL 1.08
- SUPN 1.10
- MACD
- SDRL 0.25
- SUPN -0.13
- Stochastic Oscillator
- SDRL 87.85
- SUPN 97.91
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.